We di dɔktɔ tɛl yu se yu gɛt bɔdi kansa, yu go dɔn fil bɔku fred ɛn shɔk. ‘Wetin a de du naw?’, ‘Us kayn mɛrɛsin dɛn go gi mi?’, ‘A go gɛt kemo ?’. Bɔku kwɛstyɔn dɛn go dɔn kam na mi maynd. Wi no se fɔ fɛt kansa nɔto izi waka. Bɔt tide di mɛdikal sayɛns dɔn go bifo bɔku. Na dis kayn tɛm, tide wi de tɔk bɔt wan spɛshal tɛst we de ɛp dɔktɔ dɛn fɔ disayd ustɛm fɔ gi yu.
Wetin na Ɔnkotayp DX?
Fɔ tɔk am simpul wan, Oncotype DX na spɛshal tɛst we de luk dip wan pan yu brɔst kansa sɛl dɛm. Nɔto blɔd tɛst ɔltɛm. I de yuz wan pat pan di kansa tisu we dɛn tek frɔm bayɔpsi fɔ kɔnfirm yu kansa ɔ frɔm ɔpreshɔn fɔ pul di tumbu.
Dis tεst de luk pan di wok we sכ m jin dεm de du insay di kεnsar sεl dεm. Jɔs lɛk ɔl wi sɛl dɛn, kansa sɛl dɛnsɛf gɛt jin dɛn. Dɛn jin ya de sho aw di kansa de biev, dat na aw i bad, aw i kin skata kwik kwik wan, ɛn aw i kin kam bak afta dɛn dɔn trit am.
di Oncotype DX tεst de fכkus pan 21 jin dεm, na dat mek yu kin yεri dεn kכl am “21-jin signature” tεst. We dɔktɔ dɛn stɔdi dɛn jin dɛn ya, dɛn kin lan bɔku impɔtant tin dɛn bɔt yu kansa.
Udat dɛn kin advays fɔ tek dis tɛst?
Dis tɛst nɔ nid fɔ ɛvri pɔsin we gɛt bɔdi kansa. Yu dɔktɔ go mɔs tɛl yu fɔ du dis tɛst if yu gɛt ɛni wan pan dɛn tin ya:
- If yu gɛt kansa we dɔn bigin (Stej I ɔ II): Dis min se di kansa nɔ dɔn spre yet to di say dɛn we de fa na di bɔdi.
- If di kansa na εstrojen-rεsεptor positifu (ER+): Dis min se di kansa sεl dεm de gro biכs fכ di כmon εstrojen we yu bכdi de mek. Dɛn kin trit dis kayn kansa wit ɔmon tɛrapi .
- If di kansa nɔ dɔn spre to di limf no dɛm na di leg.
Apat frɔm dat, sɔm tɛm dɛn kin du dis tɛst fɔ pipul dɛn we gɛt kansa we dɛn kin kɔl DCIS (Ductal Carcinoma in Situ) , fɔ ɛp fɔ disayd if dɛn nid fɔ gɛt raytin tɛrapi.
Di tin we impɔtant pas ɔl na dat di big ɛp frɔm dis tɛst na di gayd we yu kin gɛt fɔ disayd if yu nid kimotɛrapi tritmɛnt ɔ nɔ nid am apat frɔm ɔmon tɛrapi.
Aw yu kin rid di tɛst skɔ?
Di Oncotype DX test de gi yu “Recurrence Score” bitwin 0 ɛn 100. Di mɔ dis skɔ, na di mɔ di risk fɔ mek di kansa kam bak afta tritmɛnt. Bɔt di we aw dɛn de rid dis mak go difrɛn smɔl fɔ di ej we yu ol.
| Skɔ Rɛnj | Denja | Sɔntɛm Rikɔmɛndishɔn |
|---|---|---|
| 0 – 25. Di wan dɛn we de wok | Low risk | Ɔmon tritmɛnt nɔmɔ kin du fɔ am. Na smɔl chans de fɔ mek dɛn gɛt mɔ bɛnifit frɔm kemotɛrapi. |
| 26 – 100, ɛn 100 | Risk we pas ɔl | Di risk fɔ mek di kansa kam bak kin bɔku. Dɛn kin se dɛn fɔ tek kimotɛrapi ɛn dɛn kin tɛl yu bak fɔ tek ɔmon. |
| Skɔ Rɛnj | Denja | Sɔntɛm Rikɔmɛndishɔn |
|---|---|---|
| 0 – 15. Di wan dɛn we de wok | Low risk | Ɔmon tritmɛnt nɔmɔ kin du fɔ am. Na smɔl chans de fɔ mek dɛn gɛt mɔ bɛnifit frɔm kemotɛrapi. |
| 16 – 20, ɛn 20 | Lɔw-mɛdiɔm risk | Kimotɛrapi kin gi smɔl bɛnifit, bɔt yu fɔ tɔk to yu dɔktɔ if di bɛnifit fayn we yu kɔmpia am to di bad tin dɛn we kin apin to yu. |
| 21 – 25, ɛn di ɔda wan dɛn | Midul risk | Di bɛnifit dɛn we kemotɛrapi kin gi kin pas di bad tin dɛn we kin apin to pɔsin. Yu fɔ tɔk bɔt dis wit yu dɔktɔ ɛn disayd fɔ du sɔntin. |
| 26 – 100, ɛn 100 | Risk we pas ɔl | Di risk fɔ mek kansa kam bak kin bɔku. Dɛn kin se dɛn fɔ tek kimotɛrapi wit ɔmon tɛrapi. |
Yu tink se na dis sayn nɔmɔ fɔ sho di tritmɛnt?
Nɔto so i bi atɔl. Dis rili impɔtant. Di Oncotype DX skɔ na wan strɔng tin nɔmɔ fɔ ɛp yu fɔ disayd. Yu dɔktɔ go tek bɔku ɔda tin dɛn na yu maynd bifo i mek di bɛst tritmɛnt plan fɔ yu.
Fɔ ɛgzampul:
- Tumɔr saiz
- Tumor gred
- di nכmba fכ di כmon rεsεpכta dεm na di kεnsar sεl dεm
- Yu ej ɛn ɔl yu wɛlbɔdi
Ɔl dɛn tin ya kin kam togɛda fɔ disayd fɔ du di las tin. So, dis tɛst ripɔt na jɔs wan tin we go ɛp yu dɔktɔ fɔ mek di bɛst tritmɛnt plan fɔ yu.
Ɔda jenɛtik tɛst dɛn de lɛk dis?
Yɛs, sɔm ɔda jenɛtik tɛst dɛn de we dɛn kin yuz fɔ gɛt kansa na in bɔdi. Bɔt di wan we dɛn kin yuz mɔ na stil Oncotype DX. Lɛ wi lan smɔl bɔt di ɔda wan dɛn.
- MammaPrint: Dis de tεst fכ 70 jin dεm. I de ɛp fɔ no di risk fɔ mek kansa skata na do na di bɔdi. i kin yuz fכ כl tu di ER+ εn ER- tכp dεm.
- Mammostrat: Dis de tεst 5 jin dεm εn de mכsu di risk fכ di εli stej כmon-rεsεptor positifu brεst kεnsar we de kam bak.
- Prosigna: Dɛn kin yuz dis fɔ ɔmon-rɛsɛptɔ-pɔzitiv brɔst kansa pan uman dɛn we dɔn pas 40 ia. I de analayz 58 jin dɛm ɛn prɛdikt di risk fɔ mek di kansa kam bak ɔdasay na di bɔdi insay 10 ia.
Ɔl dɛn tin ya na tɛst dɛn we dɔn go bifo. Yu dɔktɔ go disayd if yu nid wan pan dɛn tin ya ɛn uswan go fayn fɔ yu.
Mɛsej we dɛn kin kɛr go na os
- Oncotype DX na spɛshal tɛst we de chɛk di jin dɛm fɔ di brɛst kansa sɛl dɛm fɔ ɛp fɔ no di risk fɔ mek kansa kam bak ɛn if dɛn nid fɔ tek kemotɛrapi.
- Dɛn kin du dis wit wan pat pan di kansa tisu we dɛn tek frɔm bayɔpsi ɔ ɔpreshɔn, nɔto frɔm blɔd.
- Dis tɛst nɔ nid fɔ ɔlman. dεn kin yus am mכst fכ kεnsar dεm we na Stej I/II, ER+, εn we nכ spre to di limf no dεm.
- Di tɛst skɔ na wan pat nɔmɔ pan di tritmɛnt plan. Yu dɔktɔ go tink bɔt bɔku ɔda tin dɛn lɛk aw di kansa big, aw i siriɔs, ɛn yu ej.
- If yu gɛt ɛni kwɛstyɔn ɔ tin we de mɔna yu bɔt dis, mek shɔ se yu tɔk to yu dɔktɔ opin wan . I go mɔs ɛp yu fɔ pik wetin bɛtɛ fɔ yu.
Oncotype DX Sinhala, Breast Cancer, Kemotherapy, Kansa Jɛnɛtik Tɛst, Kansa Rikɔrɛshɔn, ER Pozitiv Kansa , Kansa Tritmɛnt
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt